It is a pleasure to write this Editorial as the Interim Editor-in-Chief of TIRS, and a privilege to shepherd the journal in the next few months towards its next Editor-in-Chief. Dr Stephen Spielberg, who stepped down from this role in December, has done an outstanding job during his four-year tenure, and it is fitting to acknowledge his successes here. It is also appropriate to acknowledge the sterling work done for DIA for many years by Ms Judy Connors, who has also transitioned to new ventures. Very best wishes are extended to both of them. Also, I'd like to welcome onboard Dr Ranjini Prithviraj, who joined DIA last November as Senior Managing Editor and Associate Director of DIA Publications. She brings several years of science publishing experience to her new role, and I look forward to a very productive collaboration with her.
A recent announcement by the US Food and Drug Administration (FDA) has attracted considerable attention in the therapeutic areas of type 2 diabetes (T2D), cardiovascular disease, and renal disease. Various aspects of this decision and announcement are well captured by both components of our journal's name, "Therapeutic Innovation" and "Regulatory Science," and it is appropriate to share this news with our readers. On December 2, 2016, the FDA announced a new indication for empagliflozin, 1 a sodium-glucose cotransporter 2 (SGLT-2) inhibitor originally approved by FDA in August 2014 as an addition to diet and exercise to improve glycemic control in adults with T2D. 2 The new indication for empagliflozin is to reduce the risk of cardiovascular death in adult patients with T2D and established cardiovascular disease. A very reasonable question is, How did a drug originally indicated for T2D receive a cardiovascular indication?
Diabetes is associated with a 2-to 4-fold increased risk of cardiovascular disease, 3 and it is therefore important that drugs administered for this disease do not unintentionally increase that risk further. Since December 2008, the FDA has required that all new antidiabetic drugs for T2D be prospectively exonerated from an unacceptable cardiovascular risk. 4 Such exoneration typically occurs in two steps. At the time of filing a New Drug Application (NDA), the sponsor is expected to have ruled out an excess cardiovascular risk of 80% or greater. If the drug is approved, the sponsor needs to conduct additional research, typically in the form of a large cardiovascular safety outcome trial, that will enable the drug to be exonerated from a more rigorous criterion, that is, an excess cardiovascular risk of 30% or greater. 5 At the time of awarding marketing approval to empagliflozin in August 2014, FDA therefore required the completion of an ongoing cardiovascular safety outcome trial, the EMPA-REG OUTCOME study, to satisfy the second requirement.
EMPA-REG OUTCOME 6 adopted a major adverse cardiovascular events (MACE) composite endpoint comprising death from cardiovascular causes, nonfatal myocardial infarction (MI), and nonfatal stroke. The statistical operationalization of the requirement to exonerate a drug from an excess cardiovascular risk of 30% or greater involves calculating the hazard ratio (HR) point estimate for the MACE composite endpoint for the drug versus the comparator drug, and then placing a two-sided 95% confidence interval (CI) around the HR point estimate. If the upper limit of the CI lies below 1.3 the requirement is met. As an example of this occurrence, consider the results from the SAVOR-TIMI 53 cardiovascular safety outcome study conducted for the antidiabetic drug saxagliptin, a dipeptidyl peptidase 4 inhibitor. 7 This trial also employed a MACE composite endpoint. The main result was HR ¼ 1.00 (95% CI: 0.89-1.12). This can be interpreted as follows: The result from this trial is compatible with an increase in cardiovascular risk of as great as 12% and also with a decrease in cardiovascular risk of as great as 11%, and the best estimate is no change in risk. Since the upper limit of the CI (1.12) fell below 1.3, saxagliptin was exonerated from an unacceptable increase in cardiovascular risk.
Consider now the result for the MACE composite endpoint from EMPA-REG OUTCOME: HR ¼ 0.86 (95% CI: 0.74-0.99, P < .05). This can be interpreted as follows: The result from this trial is compatible with a decrease in cardiovascular risk of as little as 1% and as great as 26%, and the best estimate is a decrease of 14%. Since the upper limit of the CI (0.99) fell below 1.3, empagliflozin was exonerated from an unacceptable increase in cardiovascular risk. Moreover, in this case the upper limit of the CI also fell below 1.00, a value that represents neither increase nor decrease in risk. That is, the "worst-case scenario" 8 here is a small (1%) decrease in risk, an occurrence that provides statistical significance at the P <.05 level to this result. The trial therefore provided evidence of cardiovascular benefit. Of additional importance was the result for one of the three individual components of the MACE composite endpoint, death from cardiovascular causes: HR ¼ 0.62 (95% CI: 0.49-0.77, P < .05). This can be interpreted as follows: The result from this trial is compatible with a decrease in cardiovascular risk of as little as 23% and as great as 51%, and the best estimate is a decrease of 38%. There were no significant between-treatment-group differences for risk of nonfatal MI and nonfatal stroke. 6 Following the results from EMPA-REG OUTCOME, empagliflozin's sponsor submitted two supplemental NDAs, one for empagliflozin tablets and one for empagliflozin and metformin fixed-dose combination tablets. FDA subsequently convened a meeting of its Endocrinologic and Metabolic Drugs Advisory Committee on June 28, 2016. 9 Following discussions, committee members voted 23 to zero that the EMPA-REG OUTCOME results fulfilled FDA's requirements to exonerate the drug from an unacceptable cardiovascular liability. They then provided answers to the question "Based on data in the briefing materials and presentations at today's meeting, do you believe the EMPA-REG OUTCOME study results provide substantial evidence to establish that empagliflozin reduces cardiovascular mortality in the population studied?" Twelve members voted yes and 11 members voted no. Advisory Committee votes are not binding on FDA, but on this occasion the agency agreed with those who voted yes, and as noted previously, on December 2, 2016, they approved a new indication for empagliflozin to reduce the risk of cardiovascular death in adult patients with T2D and established cardiovascular disease. 1 Of particular interest to nephrologists was a subsequent report from the EMPA-REG OUTCOME investigators focusing on a secondary endpoint that was a composite of microvascular outcomes. 10 When added to standard care, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo in individuals with T2D at high cardiovascular risk.
The new cardiovascular indication for empagliflozin and potentially similar indications for other antidiabetic drugs (liraglutide 11 and semaglutide 12 have also recently been reported to confer cardiovascular benefit to adults with T2D) may have far-reaching implications in the treatment of individuals with T2D and cardiovascular disease, and potentially those with renal disease. Such consequences will of considerable interest to many clinical scientists and to physicians in the interdisciplinary community involved in the management of such patients, for example, endocrinologists, cardiologists, nephrologists, and primary care physicians. 13 Additionally, there are already discussions in the literature about expansion of this line of research to individuals without T2D. MacIsaac and colleagues, for example, recently observed that "without doubt, trials to investigate whether SGLT-2 inhibitors have cardio-renal protective effects in patients without diabetes will start soon." 14 We will keep readers appraised of future developments in this therapeutic area.
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